These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25554535)

  • 1. Erroneous event count in a meta-analysis (dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus).
    Buisson M; Cornu C; Nony P
    Am J Cardiol; 2015 Mar; 115(6):852. PubMed ID: 25554535
    [No Abstract]   [Full Text] [Related]  

  • 2. [DPP4 inhibitors: what is the cardiovascular risk?].
    Langrand C; Moulin P
    Rev Prat; 2015 Oct; 65(8):1039-41. PubMed ID: 26749701
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply: To PMID 22703861.
    Albadarin F; Bell DS; O'Keefe JH
    Am J Cardiol; 2015 Mar; 115(6):852-3. PubMed ID: 25728847
    [No Abstract]   [Full Text] [Related]  

  • 4. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: decongesting the matter.
    Vaduganathan M; Bhatt DL
    Eur Heart J; 2015 Jun; 36(24):1497-8. PubMed ID: 26295082
    [No Abstract]   [Full Text] [Related]  

  • 5. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.
    Patil HR; Al Badarin FJ; Al Shami HA; Bhatti SK; Lavie CJ; Bell DS; O'Keefe JH
    Am J Cardiol; 2012 Sep; 110(6):826-33. PubMed ID: 22703861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus.
    Kaneko M; Narukawa M
    Diabetes Res Clin Pract; 2016 Jun; 116():171-82. PubMed ID: 27321333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pooled patient level data are better suited than study level data to investigate the link between dipeptidyl peptidase-4 inhibitors and the risk of heart failure in type 2 diabetes.
    Patel T; Tesfaldet B; Gandotra C;
    BMJ; 2016 May; 353():i2920. PubMed ID: 27220716
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials.
    Abbas AS; Dehbi HM; Ray KK
    Diabetes Obes Metab; 2016 Mar; 18(3):295-9. PubMed ID: 26510994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.
    Elgendy IY; Mahmoud AN; Barakat AF; Elgendy AY; Saad M; Abuzaid A; Wayangankar SA; Bavry AA
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):143-155. PubMed ID: 27873238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase-iV inhibitors: fixing type 2 diabetes?
    McIntyre HF; Grant P
    Br J Hosp Med (Lond); 2007 Nov; 68(11):599-602. PubMed ID: 18087847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inclusion of the EXAMINE study in a meta-analysis of the addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia.
    Boucaud-Maitre D
    BMJ; 2016 Jun; 353():i3186. PubMed ID: 27267596
    [No Abstract]   [Full Text] [Related]  

  • 13. No increased heart failure risk is reported with DPP-4 inhibitors.
    Wise J
    BMJ; 2016 Apr; 353():i2363. PubMed ID: 27118534
    [No Abstract]   [Full Text] [Related]  

  • 14. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: the importance of the pharmacotherapeutic history.
    García-Gil MF; Lezcano Biosca V; García García M; Monte Serrano J; Aldea Manrique B
    Postgrad Med J; 2021 Jan; 97(1143):51-52. PubMed ID: 32198232
    [No Abstract]   [Full Text] [Related]  

  • 16. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
    Green JB
    Postgrad Med; 2012 Jul; 124(4):54-61. PubMed ID: 22913894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recommendations of the main clinical practice guidelines].
    Miravet I Jiménez S
    Semergen; 2018 Jun; 44 Suppl 1():3-9. PubMed ID: 30322471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preying on the pancreas? Scientists debate whether newer diabetes medications do harm.
    Berg EG
    Diabetes Forecast; 2013 Oct; 66(10):26, 28, 30-1. PubMed ID: 24224353
    [No Abstract]   [Full Text] [Related]  

  • 19. The safety of incretin based drug treatments for type 2 diabetes.
    Bolen SD; Maruthur NM
    BMJ; 2016 Feb; 352():i801. PubMed ID: 26888024
    [No Abstract]   [Full Text] [Related]  

  • 20. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
    Xu L; Spinas GA; Niessen M
    Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.